Unlock instant, AI-driven research and patent intelligence for your innovation.

glp-1 fusion protein comprising a mutated immunoglobulin fc portion

A technology of immunoglobulin and GLP-1, applied in peptide/protein components, medical preparations containing active ingredients, fusion polypeptides, etc., can solve the problems of short biological half-life and difficult concentration detection

Active Publication Date: 2021-09-28
SUNSHINE LAKE PHARM CO LTD
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The biological half-life of GLP-1 is short, 1-1.5min, and it is quickly degraded by dipeptidase IV. Therefore, it is difficult to detect its concentration in blood clinically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • glp-1 fusion protein comprising a mutated immunoglobulin fc portion
  • glp-1 fusion protein comprising a mutated immunoglobulin fc portion
  • glp-1 fusion protein comprising a mutated immunoglobulin fc portion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] The construction of embodiment 1 carrier

[0112] Based on the above-mentioned technical route, adopt the method for molecular cloning, construct the following (from N-terminal to C-terminal) various expression vectors of the present invention:

[0113] GLP-1 analogue (amino acid sequence shown in SEQ ID NO.6)+peptide linker (amino acid sequence shown in SEQ ID NO.7)+mutated immunoglobulin Fc part.

[0114] The amino acid sequences of the constructed fusion proteins are respectively shown in SEQ ID NOs. 1-4, 8-11.

[0115] As a control, construct a vector encoding the following (from N-terminus to C-terminus):

[0116] For dulaglutide (WT), the amino acid sequence is shown in SEQ ID NO.5.

[0117] The mutated immunoglobulin Fc portion of the present invention is summarized as follows:

[0118] Table 1

[0119]

[0120] The nucleotide sequences encoding the WT fusion protein (dulaglutide) and the IgG4-Fc mutant fusion protein were obtained by chemical synthesis ba...

Embodiment 2

[0121] Example 2 Vector transfection and expression in cells

[0122] After recovering CHO host cells with CHO medium, when the cell density is about 8x10 5 Cells were harvested for transfection at 1 cells / mL. Transfected cells about 1x10 7 Each cell was transfected with about 40 μg of plasmid (Bio-Rad, Genepulser Xcell) by electroporation. Cells were cultured in 20 mL CHO medium after electric shock. On the second day of culture, the cells were collected by centrifugation, and resuspended in 20 mL of CHO medium added with G418 (Geneticin) to a final concentration of 800 μg / mL. When the cell density is about 0.6x10 6 cells / mL, the obtained mixed clones were subcultured in CHO medium, and the subcultured cell density was about 0.2x10 6 cells / mL. When the cell survival rate was about 90%, the cell culture fluid was collected.

Embodiment 3

[0123] Embodiment 3 purifies fusion protein from animal cell culture fluid

[0124] A series of fusion proteins in Example 1 were tested at the translation level. Use Protein A filler to enrich a small amount of cell culture fluid, and collect the fusion protein. The obtained fusion protein is a homodimer formed by disulfide bonds and various non-covalent interactions. Mass spectrometry is used to detect the molecular weight. About 62KD, consistent with the theoretical molecular weight. The collected fusion protein was purified using Protein A chromatography column. The collected samples were detected by 10% SDS-PAGE electrophoresis after reduction, and the electrophoresis pattern showed a single band, about 36KD. Purified samples were dialyzed overnight at 4°C against 10 mM PBS buffer, pH 7.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to fusion proteins comprising GLP-1 or an analog thereof, a peptide linker and a mutated Fc portion of an immunoglobulin, which have increased half-life. The invention also provides a method for producing the fusion protein and the application of the fusion protein in the preparation of medicines.

Description

technical field [0001] The present invention relates to a fusion protein of glucagon-like peptide-1 (GLP-1), which comprises a mutated immunoglobulin Fc part, thus having a prolonged half-life in vivo. The fusion protein can be used to treat diabetes, obesity and other related diseases or conditions. Background technique [0002] Glucagon-like peptide-1 (GLP-1) was originally isolated from the intestinal mucosa and is a brain-gut peptide secreted by ileal endocrine cells. It is currently mainly used as a type 2 diabetes drug target of action. Since GLP-1 can inhibit gastric emptying and reduce intestinal peristalsis, it helps to control food intake and reduce weight. [0003] The GLP-1 initially produced in the intestine is 37 peptide, which is an inactive peptide chain. It needs to be enzymatically excised to remove the N-terminal 6-peptide to become biologically active GLP-1 (7-37), and its C-terminal glycine can be used as amidation In this way, about 80% of the GLP-1 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62A61K38/26A61K47/68A61P3/10A61P3/04
CPCC07K14/605A61K38/00C07K2319/30C07K19/00C12N15/62A61P3/04A61P3/10
Inventor 张宇博李利佳贺铁凡许玲华刘亮陈小锋李文佳
Owner SUNSHINE LAKE PHARM CO LTD